VANFLYTA 17.7 mg, film-coated tablet 28 tablets
Active ingredients: DICHLORHYDRATE DE QUIZARTINIB, QUIZARTINIB
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VANFLYTA 17,7 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 28 plaquettes aluminium de 1 comprimé
- Marketing authorisation holder
- DAIICHI SANKYO EUROPE (ALLEMAGNE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Feb 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69293541CIP73028263CIP133400930282632Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DICHLORHYDRATE DE QUIZARTINIBcomprimé | — | SA |
| QUIZARTINIBcomprimé | 17,7 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.